07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Synthesis of therapeutic peptides resistant to degradation by serine proteases A method to render therapeutic peptides resistant to serine proteases could...
07:00 , May 23, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fibroblast activation protein (FAP) In vitro studies identified a boronic acid-based inhibitor of FAP that could be useful for treating cancer. Increased FAP activity...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

ARI-3037MO: Phase I data

Data from a pair of placebo-controlled Phase I trials in 58 healthy volunteers total showed that single and multiple ascending-doses of once-daily ARI-3037MO for 14 days were well tolerated with no treatment-related adverse events reported....
07:00 , Mar 28, 2011 |  BC Week In Review  |  Clinical News

ARI-3037MO: Phase I start

This month, Arisaph will begin a placebo-controlled, dose-escalation Phase I trial to evaluate a single dose of once-daily ARI-3037MO in about 40 healthy volunteers. Arisaph said it plans to start a multiple ascending-dose Phase Ib...
08:00 , Nov 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Apolipoprotein A-1 (APOA1) Cell culture and mouse studies suggest that APOA1 peptide mimetics could help treat ovarian cancer. Low APOA1 serum levels are...
08:00 , Nov 8, 2010 |  BioCentury  |  Finance

Wanted: Less Dilution

The $1 billion in therapeutic tax credit money doled out by the U.S. Treasury last week was spread so thinly among 3,000 companies that biotech CEOs are already looking at ways to make a hoped-for...
07:00 , Oct 2, 2008 |  BC Innovations  |  Cover Story

Truly Boronic

Researchers at Tufts University have shown that peptide boronic acid inhibitors of dipeptidyl peptidase-4 could provide effective, low-toxicity treatments for diabetes. 1 The findings challenge the long-held assumption that boronic acids are too toxic for...
07:00 , Sep 25, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Type 2 diabetes Dipeptidyl peptidase-4 (DPP-4); DPP-8; DPP-9 Studies in rodents and in human cells suggest that DPP-4-specific, dipeptide...
07:00 , Mar 17, 2008 |  BC Week In Review  |  Clinical News

ARI-2243: Phase I start

This half, Arisaph will begin a dose-escalation Phase I trial of oral ARI-2243 given once daily in healthy volunteers. Arisaph Pharmaceuticals Inc. , Boston, Mass.   Product: ARI-2243   Business: Endocrine   Molecular target: Dipeptidyl...
07:00 , Aug 27, 2007 |  BioCentury  |  Strategy

Targeting DPP-4

Targeting DPP-4 Company Product Status Novartis Galvus vildagliptin (LAF237) FDA approvable letter (resubmit NDA mid-09) AstraZeneca/Bristol-Myers/Otsuka Saxagliptin Ph III (submit NDA 1H08) Takeda Alogliptin (SYR322) [from Syrrx acq] Ph III Phenomix PHX1149 Ph IIb Glenmark/...